Fiera Capital Corp Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Fiera Capital Corp increased its stake in Alnylam Pharmaceuticals by 7.8% in the first quarter, owning a total of 17,212 shares valued at approximately $4.65 million.
• Analysts have raised their price targets for Alnylam shares significantly, with estimates ranging from $333.00 to $500.00, reflecting a strong market sentiment towards the company's growth prospects.
• CEO Yvonne Greenstreet sold 31,640 shares in May at an average price of $304.39, reducing her ownership by 39.26%, which may raise questions regarding insider confidence.

Fiera Capital Corp boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,212 shares of the biopharmaceutical company's stock after buying an additional 1,242 shares during the quarter. Fiera Capital Corp's holdings in Alnylam Pharmaceuticals were worth $4,648,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the period. Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Finally, Washington Trust Advisors Inc. grew its position in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 61 shares during the period. Institutional investors own 92.97% of the company's stock.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ALNY shares. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an "overweight" rating in a report on Wednesday, July 16th. Piper Sandler lifted their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a report on Friday. Citigroup lifted their target price on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a report on Friday, July 11th. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a report on Friday. Finally, UBS Group lifted their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $392.13.

Alnylam Pharmaceuticals Stock Up 2.4%

NASDAQ:ALNY traded up $9.56 on Friday, reaching $401.80. The stock had a trading volume of 1,780,984 shares, compared to its average volume of 1,028,799. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $402.43. The company has a 50-day moving average of $318.24 and a 200 day moving average of $278.61. The stock has a market cap of $52.39 billion, a P/E ratio of -162.67 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 444.38% and a negative net margin of 12.96%. The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same period in the prior year, the business earned ($0.16) EPS. The business's revenue was up 20.2% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.